In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Optical coherence tomography non-inferior to intravascular ultrasound for stent guidance

OCTIVUS trial presented in a Hot Line Session today at ESC Congress 2023

Invasive Imaging and Functional Assessment
Coronary Intervention

Amsterdam, Netherlands – 27 Aug 2023: Optical coherence tomography (OCT) is non-inferior to intravascular ultrasound (IVUS) for guiding percutaneous coronary intervention (PCI), according to late breaking research presented in a Hot Line session today at ESC Congress 2023.1

IVUS and OCT have been increasingly used to guide PCI procedures. Both imaging techniques can be used to assess target lesion characteristics, optimise stent implantation and minimise stent-related problems. European and US guidelines recommend that IVUS or OCT be considered in selected patients to optimise stent implantation.2,3 However, the comparative effectiveness of these two contemporary imaging strategies for PCI guidance are still unknown.

The OCTIVUS trial was a head-to-head comparison of OCT- and IVUS-guided PCI with regards to clinical outcomes in patients with a broad range of coronary artery lesions.

The trial was an investigator-initiated, prospective, multicentre, randomised, open-label pragmatic trial conducted at nine sites in South Korea. It enrolled patients aged 19 years or older who were undergoing PCI with contemporary drug-eluting stents or drug-coated balloons (only for in-stent restenosis) for significant coronary artery lesions. As a pragmatic trial, the enrolment criteria were designed to capture a broad range of patients with various anatomical or clinical characteristics.

A total of 2,008 patients were randomised in a 1:1 ratio to undergo either OCT-guided or IVUS-guided PCI after diagnostic coronary angiography. The average age of participants was 64.7 years and 21.6% were women. Overall, 33.4% of patients had diabetes, 76.6% presented with stable ischaemic heart disease and 23.4% presented with an acute coronary syndrome.

The primary endpoint was a composite of death from cardiac causes, target vessel myocardial infarction or ischaemia-driven target vessel revascularisation at one year, which was powered for noninferiority of the OCT group as compared with the IVUS group (noninferiority margin, 3.1 percentage points).

At one year after randomisation, the primary endpoint had occurred in 25 of 1,005 patients (2.5%) in the OCT-guided PCI group and in 31 of 1,003 patients (3.1%) in the IVUS-guided PCI group (risk difference, −0.6 percentage points; upper boundary of the one-sided 97.5% confidence interval, 0.97; p<0.001 for noninferiority).

Regarding safety endpoints, the incidence of contrast-induced nephropathy was similar in the OCT and IVUS groups (1.4% vs. 1.5%, respectively). The incidence of major procedural complications was lower in the OCT group compared with the IVUS group (2.2% vs. 3.7%; p=0.048).

The total amount of contrast used was higher in the OCT group compared with the IVUS group (average of 238.3 vs. 199.8 mL; p<0.001), but the total PCI time was shorter in the OCT group (mean 46.1 vs. 48.9 minutes; p<0.001).

Principal investigator Professor Duk-Woo Park of Asan Medical Center, Seoul, Republic of Korea said: “Among patients undergoing PCI for diverse coronary artery lesions, OCT-guided PCI was noninferior to IVUS-guided PCI with respect to a composite of death from cardiac causes, target vessel myocardial infarction, or ischemia-driven target vessel revascularisation at 12 months after the index procedure. The primary results of OCTIVUS add compelling evidence on the relative efficacy and safety of an OCT-guided strategy compared with an IVUS-guided strategy for PCI.”



Notes to editor

ESC Press Office
Tel: +33 (0)6 61 40 18 84

The hashtag for ESC Congress 2023 is #ESCCongress

Follow us on Twitter @ESCardioNews 


This press release accompanies both a presentation and an ESC press conference at ESC Congress 2023. It does not necessarily reflect the opinion of the European Society of Cardiology.


Funding: This study was funded by the CardioVascular Research Foundation, Abbott Vascular, and Medtronic; OCTIVUS number, NCT03394079.


Disclosures: DW Park reports research grants or speaker’s fees from Abbott Vascular, Medtronic, Daiichi-Sankyo, grants from ChongKunDang Pharm, grants from Daewoong Pharm.

References and notes

1OCTIVUS will be discussed during Hot Line 4 on Sunday 27 August at 08:30 to 10:00 CEST in room Amsterdam.

2Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40:87-165.
3Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI Guideline for coronary artery revascularization: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e18-e114.

About ESC Congress 2023

It is the world’s largest gathering of cardiovascular professionals, disseminating ground-breaking science both onsite in Amsterdam and online – from 25 to 28 August. Explore the scientific programme. More information is available from the ESC Press Office at


About the European Society of Cardiology

The ESC brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people to live longer, healthier lives.